This presentation, and its accompanying commentary, contains forward-looking statements.<br />Aradigm Corporation’s actual...
Aradigm at a Glance<br />A Leader in Pulmonary Drug Delivery<br />Technology platform is applicable to many therapeutic ar...
Benefits of AERx Pulmonary Delivery<br />Time to peak morphine concentration as fast as intravenous injection<br />Faster ...
Advanced Pulmonary Drug Delivery<br />Advantages<br />Large Surface Area<br />Near Direct Access<br />Natural Function<br ...
Nozzle Area<br />Blister Area<br />AERx Particle Size Control<br />Consistently small particles (1-3 microns)<br />Point-o...
AERx Control of Patient Inhalation<br />Device actively guides patient to breathe correctly<br />Automatically delivers dr...
AERx Platform<br />
Liquid formulation<br />Fast development<br />Unit dose disposable packet<br />Superior aerosol performance<br />Breath co...
Local Lung Delivery<br />Systemic Delivery<br />Pulmonary Delivery Applications<br />Undisclosed Phase I<br />Morphine-Pha...
Eight partner funded programs
Four phase II programs</li></li></ul><li>Leading Partner Endorsements	<br />AERx Diabetes Management System<br />AERx Pain...
Diabetes Management<br /> Requirements<br />AERx Diabetes Management System<br />Achieve Reproducibility<br />Tight contro...
Pain Management<br /> Requirements<br />AERx Pain Management System<br />Rapid, Reproducible<br />Comparable to intravenou...
Cystic Fibrosis Management<br /> Requirements<br />AERx System with Dornase Alfa<br />Fast and Simple<br />90% reduction i...
Most biotech drugs are in stable liquid formulations<br />AERx Well Positioned for Future Opportunities<br />Chronic bronc...
Development<br />Manufacturing<br />Commercial Sales<br />Aradigm Business Model- Pharma Profitability...<br />Partner pay...
Historical Income Statements<br />
Cash Summary <br />
2000 / Early 2001 Milestones<br />Advances in intellectual property position<br />Phase II insulin data at American Diabet...
Upcoming SlideShare
Loading in …5
×

Aradigm Informed Investor Conference presentation (Archived 2000)

2,521 views
2,406 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
2,521
On SlideShare
0
From Embeds
0
Number of Embeds
1,761
Actions
Shares
0
Downloads
8
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Aradigm Informed Investor Conference presentation (Archived 2000)

  1. 1.
  2. 2. This presentation, and its accompanying commentary, contains forward-looking statements.<br />Aradigm Corporation’s actual results may differ materially from those suggested here today. <br />Additional information concerning factors that would cause such a difference is contained in the Company’s 1999 Annual Report on Form 10-K.<br />Aradigm Corporation<br />
  3. 3. Aradigm at a Glance<br />A Leader in Pulmonary Drug Delivery<br />Technology platform is applicable to many therapeutic areas<br />Partnered with industry leaders<br />Novo Nordisk, SmithKline Beecham and Genentech<br />$55M invested to date<br />AERx hand-held device is convenient, simple to use and designed to prevent errors in dosing<br />
  4. 4. Benefits of AERx Pulmonary Delivery<br />Time to peak morphine concentration as fast as intravenous injection<br />Faster reduction of glucose levels with insulin than with injection<br />90% reduction in dosing time in Cystic Fibrosis<br />Achieves therapeutic levels of biotech drugs,non-invasively<br />
  5. 5. Advanced Pulmonary Drug Delivery<br />Advantages<br />Large Surface Area<br />Near Direct Access<br />Natural Function<br />Benefits<br />Non-invasive<br />Fast onset<br />Broad applicability<br />
  6. 6. Nozzle Area<br />Blister Area<br />AERx Particle Size Control<br />Consistently small particles (1-3 microns)<br />Point-of-use aerosol control<br />Single use, disposable<br />
  7. 7. AERx Control of Patient Inhalation<br />Device actively guides patient to breathe correctly<br />Automatically delivers drug at right time<br />Eliminates patient breathing as a source of error<br />
  8. 8. AERx Platform<br />
  9. 9. Liquid formulation<br />Fast development<br />Unit dose disposable packet<br />Superior aerosol performance<br />Breath control<br />Consistent dose delivery<br />Data capture<br />Enhances therapy compliance<br />The AERx Advantage<br />
  10. 10. Local Lung Delivery<br />Systemic Delivery<br />Pulmonary Delivery Applications<br />Undisclosed Phase I<br />Morphine-Phase II<br />Undisclosed-Phase I<br />Small Molecule<br />Insulin-Phase II<br />Gene Therapy-preclinical<br />Undisclosed-preclinical<br />Dornase alfa-Phase II<br />Undisclosed-Phase II<br />Gene Therapy-preclinical<br />Macro-molecule<br /><ul><li>The most broadly applicable technology
  11. 11. Eight partner funded programs
  12. 12. Four phase II programs</li></li></ul><li>Leading Partner Endorsements <br />AERx Diabetes Management System<br />AERx Pain Management System<br />AERx Respiratory Management System<br />Plus five more unannounced programs<br />
  13. 13.
  14. 14. Diabetes Management<br /> Requirements<br />AERx Diabetes Management System<br />Achieve Reproducibility<br />Tight control over particle size and breathing<br />Adjustable Dosing<br />One insulin unit increments<br />Access to Insulin<br />Novo Nordisk is the world leader in insulin<br />
  15. 15.
  16. 16. Pain Management<br /> Requirements<br />AERx Pain Management System<br />Rapid, Reproducible<br />Comparable to intravenous delivery<br />Minimize Misuse & Abuse<br />Timed lockouts and secure access<br />Access to Oncology/Pain Market<br />SmithKline Beecham has a growing oncology franchise<br />
  17. 17.
  18. 18. Cystic Fibrosis Management<br /> Requirements<br />AERx System with Dornase Alfa<br />Fast and Simple<br />90% reduction in dosing time<br />Improved Adherence with Therapy<br />Convenience and electronic compliance monitoring<br />Access to CF Market<br />Genentech is a leader in Cystic Fibrosis therapy<br />
  19. 19. Most biotech drugs are in stable liquid formulations<br />AERx Well Positioned for Future Opportunities<br />Chronic bronchitis and emphysema drugs<br />Antibodies<br />Gene therapies<br />Asthma drugs<br />Hematopoetic factors<br />Human growth factors<br />Anti-obesity drugs<br />Migraine drugs<br />Anti-Parkinson’s drugs<br />Interleukins<br />Interferons<br />Antibiotics<br />
  20. 20. Development<br />Manufacturing<br />Commercial Sales<br />Aradigm Business Model- Pharma Profitability...<br />Partner pays costs<br />10%-25% of<br />product sales<br />40%-60% gross margins<br />ARDM receives transfer price profit<br />ARDM receives royalty<br />…But With Lower Risk Profile<br />
  21. 21. Historical Income Statements<br />
  22. 22. Cash Summary <br />
  23. 23. 2000 / Early 2001 Milestones<br />Advances in intellectual property position<br />Phase II insulin data at American Diabetes Association meeting (June 2000)<br />Potential feasibility and long-term partnerships<br />Initiation of Phase IIb morphine<br />Initiation of Phase IIb dornase alfa<br />Initiation of pivotal insulin studies<br />

×